**Table S5.** Characteristics of patients with unresectable hepatocellular carcinoma treated with and without conversion therapy in propensity score matching cohort.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Characteristics** | **All**  **(*n*=20)** | **Conversion +**  **(*n*=10)** | **Conversion -**  **(*n*=10)** | ***p*-value** |
| Age, median  [Quartiles], (years) | 72  [68–78] | 73  [71–78] | 69  [65–77] | 0.35 |
| Sex (male/female), *n* | 15/5 | 7/3 | 8/2 | 1 |
| ECOG-PS (0/1), *n* | 18/2 | 8/2 | 10/0 | 0.47 |
| Etiology (HBV/HCV/NBNC), n | 3/6/11 | 0/4/6 | 3/2/5 | 0.16 |
| Platelets, median  [Quartiles], (104/μL) | 16.1  [11.7–20.6] | 18.8  [14.2–21.0] | 12.6  [10.9–18.9] | 0.36 |
| M2BpGi  [Quartiles] (C.O.I) | 1.11  [0.97–2.07] | 1.09  [0.97–1.41] | 1.61  [0.83–2.18] | 0.80 |
| Child–Pugh score (5/6), *n* | 17/3 | 8/2 | 9/1 | 1 |
| mALBI Grade (1/2a), *n* | 8/12 | 4/6 | 4/6 | 1 |
| Portal vein invasion  (absent/present), *n* | 18/2 | 9/1 | 9/1 | 1 |
| Extrahepatic spread  (absent/present), *n* | 19/1 | 10/0 | 9/1 | 1 |
| AFP, median  [Quartiles] (ng/ml) | 19  [5–176] | 88  [8–256] | 19  [6.5–36] | 0.26 |
| BCLC stage (B/C), *n* | 17/3 | 9/1 | 8/2 | 1 |
| Drug therapy  (Lenvatinib/Atezolizumab+  Bevacizumab) | 12/8 | 6/4 | 6/4 | 1 |
| Treatment line  (first line/later line), n | 19/1 | 10/0 | 9/1 | 1 |

AFP, alpha-fetoprotein; ALBI, albumin–bilirubin; BCLC, Barcelona Clinic Liver Cancer; ECOG-PS, Eastern Cooperative Oncology Group performance status; HBV, hepatitis B virus; HCV, hepatitis C virus; LEN, lenvatinib; M2BPGi mac-2 binding protein glycosylation isomer; NBNC, non-B non-C; TAE/TACE, transcatheter embolization/chemoembolization